(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The methodology of drug development has been the subject of extensive dis cussion by a relatively small group of individuals in industry and government who have been intimately concerned with the identification and study of new anticancer drugs. The Chemotherapy Program of the National Cancer In stitute has represented the major focus of initial efforts in drug development, as summarized in the historical perspective presented in chapter 1 and its references. It is no coincidence that the Chemotherapy Program was the origin of the Division of Cancer Treatment, a government entity that has had a pivotal role in the growth of clinical oncology. In an analogous fashion this book presents the methodology employed in the clinical study of anticancer drugs within the broad context of cancer treatment. The research orientation promulgated in the study of new drugs is a central theme in most oncolo gists' approach to the clinical problem of cancer. Therefore, we hope that this book will introduce readers to treatment research in clinical oncology. For the oncologist, the clinical evaluation of antitumor therapy is both part of the day-to-day management of specific patients and the critical considera tion of developing therapeutic alternatives. For physicians in other fields of medicine it is important to acquaint themselves with the basic tools of the oncologist. For people without medical training, including patients who might be interested in treatment research, many of the chapters may be overly technical.
Contents:
1. General issues in anticancer drug development.- 2. Animal tumor models for experimental therapy.- 3. Experimental therapy: In vitro models.- 4. Clinical Evaluation: Noninvasive methods.- 5. Clinical evaluation: Biochemical methods.- 6. Anatomic and surgical principles in cancer clinical trials.- 7. Experimental toxicology.- 8. The phase I study: General objectives, methods, and evaluation.- 9. Clinical evaluation of anticancer treatments: Phase II clinical trials.- 10. Analysis of clinical trial data.- 11. The strategy of cancer treatment.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: September, 2013
Pages: 220
Weight: 367g
Availability: Available
Subcategories: Oncology
From the same series
Dirk J. Ruiter
R. Verley
H.F. Seigler
Kenneth V. Honn
P. Hilgard
Noburo Kobayashi
James M. Church
L. Dogliotti
A. Giacosa
Seymour Garte
John Masters
Kintomo Takakura
B.A. Stoll
J. Mark Elwood
Laurence H. Baker
Laurence H. Baker
George D. Demetri
B.A. Stoll
A. Giacosa
Franco M. Muggia
Matthew J. van Zwieten
L.A. Liotta
Kenneth A. Foon
P.I. Reed
Paul H. Sugarbaker
Gabriel A. Kune
Frederick A. Valeriote
R. Ceriani
B. Lowenberg
D.G. Poplack
J. Bánóczy
Thomas R. Tritton
Miles P. Hacker
Aaron Polliack
B. Lowenberg
Pelayo Correa
Alexander H.G. Paterson
Franco M. Muggia
J. Aisner
Stephen T. Sonis
F.J. Cleton
Kenneth V. Honn
Stephen T. Sonis
Soldano Ferrone
Stephen B Howell
C.C. Tijssen
B.W. Hancock
B.W. Ongerboer de Visser
A.P.M. Heintz
B.A. Stoll
A.M. Ward
Daniel L. Kisner
Marvin A. Rich
J. Gordon McVie
J.R. Ryan
Marvin A. Rich
Kenneth V. Honn
D.G. Poplack
Anthony J. Mastromarino
Frederick A. Valeriote
Marvin A. Rich
Laurence H. Baker
P.K. Pattengale
G.B. Snow
Frederick A. Valeriote